Genentech Inc. (GNE)
Barbara Hoffman of Piper Jaffray said that positive data on Pulmozyme DNase presented at the North American Cystic Fibrosis Conference will lead to greater acceptance of the drug in moderately ill patients and expanded use in severely ill patients (see Clinical results, B5).